Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.
  • Page:
  • 1
  • 2
  • 3
  • 4

will the sun shine? (SUN)     

JRM - 03 Nov 2003 14:40

As a new investor I am at a loss to know why this little gem never goes anywhere

Is is a medical company with no debt, a profit!, minimal market capital and some interesting products.

We're in the shares4 schools contest and we'd like this babe to fly!

JRM - 14 Aug 2013 18:33 - 66 of 76

Just gone back in........The interims next month should benefit from the profits too late to go into last year's finals!

skinny - 16 Aug 2013 07:21 - 67 of 76

Trading Update

SI has had a strong first six months of the financial year and continues to trade in line with market expectations for the full year. Revenues for the six months ended 30 June 2013 were 28% ahead of the same period last year at £3.88m (H1 2012: £3.02m) with an adjusted EBITDA for the period of £1.14m (H1 2012: £0.98m), a 16% improvement on the previous period. Profit before tax for the period of £567,000 (H1 2012: £181,000) has more than tripled.

Within the SI Brand business, the YelloPort+plus™ Port access system continued to gain UK market share as a cost effective solution for laparoscopic surgical procedures. Further to the update provided in the AGM Statement on 19 June 2013, two additional UK hospitals have converted to using our Resposable® products, one to the YelloPort+plus™ system and one to using Logi™Cut scissors. This takes the total number of hospitals converted this year to 25. The UK success of SI Branded products promotes adoption within our targeted export markets, with the US a primary focus for the Company where hospital cost reduction programmes are becoming an ever increasing phenomenon. Both orders and interest to date, ledby our newly appointed President of US Sales and Operations, are very encouraging as we expand our Brand exposure in the US.

The OEM business primarily focused on sales of instrumentation and retraction devices, driven by a demand from the existing OEM customer base. Revenues from Industrial applications will benefit from the recently announced development project with our long standing partner, due for completion at the end of 2013.

Hip Arthroscopy
SI are partnering with JRI, a leading UK Orthopaedic company to investigate how early stage osteoarthritis of the hip can be treated using minimally invasive techniques. The collaboration has recently been allocated a £390,000 grant from the TSB Biomedical Catalyst Fund to support the project, which will see SI further translate its access and articulation technologies into hip arthroscopy to enable and deliver new advanced therapeutic treatments.

Update on new facility
In January SI announced that it had formally signed the Regional Growth Fund ("RGF") Final Grant Offer Letter worth £5.05m. SI can now announce that the Board has formally approved the budget for the development of a new facility. The total cost of the building project will be funded through the RGF grant and the remainder by a commercial bank mortgage, with an estimated completion date of July 2015.

Three site locations, all situated on the Eastern side of Leeds, are being assessed for the 58,000sq ft facility which will incorporate a 10,000sq ft Clinical training centre. The Directors believe that a phased move to the new site will not have any impact on short term trading or profitability, but it is expected to bring significant operational efficiencies and the new building will be planned specifically to optimise SI's production capabilities. The Clinical training centre will act as a catalyst for innovation enabling international surgeons to develop best clinical practice in new areas of MIS, use and critique SI's latest medical device technologies and importantly enable SI to expand its development programme into new areas of MIS. The centre will combine classic training methods of laparoscopic work stations with cadaveric and dissection facilities and a simulated operating room. It is envisaged that SI will develop one of the premier facilities in the UK that will support the growing demand for clinical training both from home and abroad.

The Company will announce its interim results for the six months ended 30 June 2013 on Tuesday, 10 September 2013.


skinny - 10 Sep 2013 07:06 - 68 of 76

Interim Results

Financial highlights
· Revenues up 28.4% to £3.88m (H1 2012: £3.02m)
· Gross margins in core MIS business increased to 45.5% (H1 2012: 44.8%)
· EBITDA up 16.8% to £1.14m (H1 2012: £976,000*)
· Operating profit* up 18.2% to £623,000 (H1 2012: £527,000*)
· Pre-tax profit* up 19.4% to £567,000 (H1 2012: £475,000*)
· Reported pre-tax profit more than tripled to £567,000 (H1 2012: £181,000)
· Adjusted basic earnings per share of 0.12p (H1 2012: 0.09p)
· Net cash of £808,000 generated from operating activities (H1 2011: £888,000*)
*comparative adjusted to exclude H1 2012 exceptional costs of £294,000

Operational highlights
· Revenues from SI branded products up 37.7% to £2.93m (H1 2012: £2.13m)
· Revenues from OEM products down 5.2% to £0.85m (H1 2012: £0.89m)
· Strong sales of Resposable® instruments with continued disposable pull through to follow
· Revenues from SI branded disposable elements up 22.8% to £1.67m (H1 2012: £1.36m)
· Impressive 144% growth in UK SI branded product revenues to £809,000 (H1 2012: £331,000)

Post-period end highlights
· Two more distributors added to growing US distribution network
· Largest ever US order, in financial terms, for SI Branded products secured in H2

skinny - 11 Sep 2013 07:50 - 69 of 76

Beaufort Securities Speculative Buy 6.75 6.75 - - Initiates/Starts

elur - 28 Oct 2013 08:44 - 70 of 76

This doesn't seem to be going anywhere and hasn't for a long time.?
Anyone have any ideas.

skinny - 05 Nov 2013 07:17 - 71 of 76

Stocking order under Surgioscopy agreement

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces it has received and dispatched an initial stocking order from Surgioscopy worth a total of £141,000.

skinny - 17 Jan 2014 07:15 - 72 of 76

Trading Update

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), provides the following trading update for the 12 months ended 31 December 2013.

Total revenues for the year ended 31 December 2013 will be £8.6m, a 13% increase against the previous year (2012: £7.6m). The Group's strategy for long term growth is the development of the SI Brand within the lucrative US market, underpinned by the appointment in May 2013 of an SI President of US Sales and Operations. The Group is therefore pleased to report a substantial increase of 75% in sales to the US of SI Branded products, through multiple new routes to market, clearly demonstrating our potential for growth and vindicating the high level of initial investment required. Overall, SI Branded product revenues have grown by 23% driven by the demand for our resposable technology.

Group profitability has been adversely affected by the combined effect of the US dollar exchange rate and more significantly the strategic investment during the second half of the year in manufacturing operations designed to streamline and improve process flows of individual product lines to enable and support the 75% growth in US revenues. As a result, the adjusted EBITDA (excluding exceptional items) for the year ended 31 December 2013 will be significantly below the reported number for the year ending December 2012 (2012: £2.9m).

ISLAHI - 29 Oct 2015 14:07 - 73 of 76

The chairman has just bought 1000000 shares at 1.3p. I have bought 120000 shares which is showing as sell in the trade

JRM - 16 Mar 2016 09:21 - 74 of 76

After a nightmare 12 months is the good news starting to flow. At £6m market capital, a new board and established custmers will the sun soon shine?

skinny - 16 Mar 2016 10:21 - 75 of 76

I'd forgotten all about these.

Final results for year ended 31 December 2015

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical technology for minimally invasive surgery, reports significantly improved financial results for the year ended 31 December 2015. Revenues and margins continue to show encouraging progress, whilst significant reductions in net operating costs, working capital and net indebtedness have been achieved.

Highlights:
· Revenues up 36% to £5.47m (2014: £4.03m)
· Gross margin improvement in second half of the year (2015: 14.0%, H1: 8.4%, H2: 19.2%)
· Adjusted EBITDA of £0.24m (2014: Adjusted EBITDA loss of £0.05m)
· Inventory reduction programme well advanced (2015: £1.92m, 2014: £4.30m)
· Net cash generated from operations of £1.57m (2014: £0.69m net cash consumed)
· Net indebtedness reduced to £2.26m (2014: £3.33m)
· New Board of directors and key management team in place
· New sales channels and products coming on stream in 2016

Executive Chairman, Nigel Rogers, said:
"In a year of transition for the Company, there have been many positive changes. Relationships with our distribution partners have been strengthened and revenues have returned to growth on solid foundations. Manufacturing and operating costs have been reduced, and working capital has been brought into line with the current needs of what is now a cash generative business.

"With these changes delivered and a solid platform secured for future growth, we now have a Board and management structure intended to drive the future direction and development of the business.

"There has been further improvement in performance in the current financial year to date. Although there remain some challenges in building on the improvements delivered in 2015, we look forward with renewed confidence."

For further information please contact:

skinny - 22 Dec 2016 12:52 - 76 of 76

Chart.aspx?Provider=EODIntra&Code=SUN&Si


Revised Banking Facilities

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, announces the revision of banking facilities made available by Yorkshire Bank ("the bank"). The existing term loan of approximately £1.70m has been repaid from available cash resources, and the bank has made available a Revolving Credit Facility of up to £1.30m for working capital and other purposes until 31 March 2020.

Nigel Rogers, Executive Chairman of SI Group, said: "Following the announcement yesterday concerning the conversion of Loan Notes, these changes to the financing structure are a major indicator of the successful transformation that the business has undergone over the last twelve months. The Company is now debt free, and can focus full attention on developing top line growth from additional products and sales channels, and the ongoing identification of suitable acquisition targets."

  • Page:
  • 1
  • 2
  • 3
  • 4
Register now or login to post to this thread.